Daily Stock Analysis, DMPI, DelMar Pharmaceuticals Inc, priceseries

DelMar Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.77
Close
0.77
High
0.79
Low
0.76
Previous Close
0.77
Daily Price Gain
-0.01
YTD High
6.29
YTD High Date
Mar 27, 2019
YTD Low
0.71
YTD Low Date
Aug 20, 2019
YTD Price Change
-2.74
YTD Gain
-78.21%
52 Week High
8.50
52 Week High Date
Sep 24, 2018
52 Week Low
0.71
52 Week Low Date
Aug 20, 2019
52 Week Price Change
-4.40
52 Week Gain
-85.17%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 25. 2017
39.00
Feb 9. 2017
46.10
11 Trading Days
18.21%
Link
LONG
Oct 30. 2017
8.89
Oct 31. 2017
9.54
1 Trading Days
7.37%
Link
LONG
Dec 28. 2017
10.60
Jan 17. 2018
14.29
12 Trading Days
34.80%
Link
LONG
Sep 7. 2018
5.60
Sep 27. 2018
7.53
14 Trading Days
34.53%
Link
LONG
Jan 4. 2019
3.60
Jan 10. 2019
3.85
4 Trading Days
6.94%
Link
LONG
Mar 15. 2019
3.39
Mar 27. 2019
4.67
8 Trading Days
37.78%
Link
LONG
Aug 8. 2019
1.61
Aug 13. 2019
2.03
3 Trading Days
26.09%
Link
Company Information
Stock Symbol
DMPI
Exchange
NasdaqCM
Company URL
http://www.delmarpharma.com
Company Phone
-
CEO
Jeffrey A. Bacha
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. It offers VAL-083; drug discovery research; as well as patents and intellectual property. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in Vancouver, Canada.

Description

DelMar Pharmaceuticals, Inc., a clinical stage company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; and collaboration with the University of Texas MD Anderson Cancer Center. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.